GlassScriptPhysician profile
Scott W Visser
NPI 1376629113
$8,118.56
in general payments reported to CMS, 2019-2025
50 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,173 · 2020: $1,389 · 2021: $1,482 · 2022: $997 · 2023: $775 · 2024: $621 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,974.28 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,596.42 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $476.50 | 2019-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $378.09 | 2019-2022 | |
| Pfizer INC. | $357.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.38 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $309.27 | 2019-2022 | |
| Amgen INC. | $301.90 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $301.04 | 2019-2023 | |
| Abbvie INC. | $198.49 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $178.01 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $113.53 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $99.07 | 2020-2021 | |
| Abbott Laboratories | $98.19 | 2019-2023 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.15 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Visser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.